ASCENTAGE PHARM. DL-0001
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibit… Read more
ASCENTAGE PHARM. DL-0001 (36X) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ASCENTAGE PHARM. DL-0001 (36X) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ASCENTAGE PHARM. DL-0001 - Net Assets Trend (None–None)
This chart illustrates how ASCENTAGE PHARM. DL-0001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ASCENTAGE PHARM. DL-0001 (None–None)
The table below shows the annual net assets of ASCENTAGE PHARM. DL-0001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ASCENTAGE PHARM. DL-0001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ASCENTAGE PHARM. DL-0001 Competitors by Market Cap
The table below lists competitors of ASCENTAGE PHARM. DL-0001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kirloskar Oil Engines Limited
NSE:KIRLOSENG
|
$1.38 Billion |
|
BBMG Corp Class A
SHG:601992
|
$1.38 Billion |
|
Lucid Group Inc
NASDAQ:LCID
|
$1.38 Billion |
|
Tabcorp Holdings Ltd
AU:TAH
|
$1.38 Billion |
|
W.T.B. Financial Corporation
PINK:WTBFA
|
$1.38 Billion |
|
Tibet Urban Development and Investment Co Ltd
SHG:600773
|
$1.38 Billion |
|
Kyland Technology Co Ltd
SHE:300353
|
$1.38 Billion |
|
LianChuang Electronic Technology Co Ltd
SHE:002036
|
$1.38 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ASCENTAGE PHARM. DL-0001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ASCENTAGE PHARM. DL-0001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ASCENTAGE PHARM. DL-0001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ASCENTAGE PHARM. DL-0001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ASCENTAGE PHARM. DL-0001 (36X) | €- | N/A | N/A | $1.38 Billion |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |